A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Phase 1TerminatedNCT01016054

Astellas Pharma Inc4 enrolled

Overview

This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.

All Subjects will receive AGS-8M4 treatment. Subjects will be enrolled into 1 of 2 treatment arms according to their disease status. A disease assessment will be performed every 8 or 9 weeks (± 3 days) depending on the treatment arm assignment. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-8M4.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Carcinoma Ovarian Cancer Ovarian Diseases Ovarian Neoplasms

Interventions

AGS-8M4BIOLOGICAL

IV infusion

Pegylated liposomal doxorubicin (PLD)DRUG

IV infusion

gemcitabineDRUG

IV infusion

carboplatin

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with recurrent disease Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma * Subjects with either platinum resistant or platinum sensitive ovarian cancer * At least 14 days of previous cytotoxic chemotherapy and have recovered from all toxicities * Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal as measured by echocardiogram or MUGA (ONLY required for platinum resistant patients) Exclusion Criteria: * Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening * Use of any investigational drug within 30 days prior to screening * Prior monoclonal antibody therapy other than Avastin * Avastin administration within 90 days of screening * History of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,DVT or PE)

Locations (1)

Unnamed facility

Duarte, California, United States

Outcomes

Primary Outcomes

Incidence of adverse events

Time frame: Throughout the treatment

Secondary Outcomes

Assessment of PK variables

Time frame: Treatment Arm A: Weeks 1 and 3 of each cycle. Treatment Arm B: Week 1 of each cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits.

Incidence of anti-AGS-8M4 antibody formation

Time frame: Treatment Arm A: Day 1 of every other cycle and at Day 15 for the first cycle only. Treatment Arm B: Day 1 of every other cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits.

Changes in tumor status per RECIST

Time frame: Treatment Arm A: Every 8 weeks. Treatment Arm B: Every 9 weeks.

Change in CA-125 levels

Time frame: Treatment Arm A: Day 1 and Day 15 of each cycle. Treatment Arm B: Day 1 of each cycle. In addition, samples will be drawn at the Safety F/U.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.